Related Experiment Video
Updated: May 24, 2026

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
Published on: May 11, 2018
An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases
Agnieszka Fiszer1, Marta Olejniczak, Pawel M Switonski
1Laboratory of Molecular Biomedicine, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Noskowskiego 12/14, 61-704 Poznan, Poland.
Background:
RNA interference (RNAi) and antisense strategies provide experimental therapeutic agents for numerous diseases, including polyglutamine (polyQ) disorders caused by CAG repeat expansion. We compared the potential of different oligonucleotide-based strategies for silencing the genes responsible for several polyQ diseases, including Huntington's disease and two spinocerebellar ataxias, type 1 and type 3. The strategies included nonallele-selective gene silencing, gene replacement, allele-selective SNP targeting and CAG repeat targeting.
Results:
Using the patient-derived cell culture models of polyQ diseases, we tested various siRNAs, and antisense reagents and assessed their silencing efficiency and allele selectivity. We showed considerable allele discrimination by several SNP targeting siRNAs based on a weak G-G or G-U pairing with normal allele and strong G-C pairing with mutant allele at the site of RISC-induced cleavage. Among the CAG repeat targeting reagents the strongest allele discrimination is achieved by miRNA-like functioning reagents that bind to their targets and inhibit their translation without substantial target cleavage. Also, morpholino analog performs well in mutant and normal allele discrimination but its efficient delivery to cells at low effective concentration still remains a challenge.
Conclusions:
Using three cellular models of polyQ diseases and the same experimental setup we directly compared the performance of different oligonucleotide-based treatment strategies that are currently under development. Based on the results obtained by us and others we discussed the advantages and drawbacks of these strategies considering them from several different perspectives. The strategy aimed at nonallele-selective inhibiting of causative gene expression by targeting specific sequence of the implicated gene is the easiest to implement but relevant benefits are still uncertain. The gene replacement strategy that combines the nonallele-selective gene silencing with the expression of the exogenous normal allele is a logical extension of the former and it deserves to be explored further. Both allele-selective RNAi approaches challenge cellular RNA interference machinery to show its ability to discriminate between similar sequences differing in either single base substitutions or repeated sequence length. Although both approaches perform well in allele discrimination most of our efforts are focused on repeat targeting due to its potentially higher universality.
Insights
Oligonucleotide strategies show promise for treating polyglutamine (polyQ) diseases by silencing disease-causing genes. Allele-selective approaches, particularly targeting CAG repeats, offer the most potential for effective and universal therapeutic development.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Polyglutamine (polyQ) disorders, including Huntington's disease, are caused by expanded CAG repeats.
- RNA interference (RNAi) and antisense strategies are being explored as therapeutic agents for these genetic disorders.
Purpose of the Study:
- To compare the efficacy and allele selectivity of various oligonucleotide-based strategies for silencing genes implicated in polyQ diseases.
- To evaluate nonallele-selective gene silencing, gene replacement, SNP targeting, and CAG repeat targeting approaches.
Main Methods:
- Utilized patient-derived cell culture models of Huntington's disease and spinocerebellar ataxias (types 1 and 3).
- Tested various small interfering RNAs (siRNAs) and antisense reagents.
- Assessed gene silencing efficiency and allele selectivity based on target binding and RISC-induced cleavage or translational inhibition.
Main Results:
- SNP-targeting siRNAs demonstrated allele discrimination by exploiting differential base pairing at the cleavage site.
- MicroRNA-like reagents targeting CAG repeats showed strong allele discrimination by inhibiting translation without significant cleavage.
- Morpholino analogs exhibited good allele discrimination but faced delivery challenges.
Conclusions:
- Oligonucleotide strategies offer diverse approaches for polyQ disease therapy, each with unique advantages and drawbacks.
- Allele-selective RNAi, especially CAG repeat targeting, shows high potential for universality and therapeutic benefit.
- Gene replacement strategies warrant further investigation as a logical extension of gene silencing approaches.

